Neuromuscular blocking drugs and their antagonists in patients with organ disease

Anaesthesia

Volumn 64, Issue SUPPL. 1, 2009, Pages 55-65

  Craig, R G ^a   Hunter, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCURONIUM; ATRACURIUM; ATROPINE; BENZYLISOQUINOLINIUM DERIVATIVE; CHOLINESTERASE INHIBITOR; CISATRACURIUM; CURARE; DIMETHYLTUBOCURARINE CHLORIDE; DOXACURIUM; GLYCOPYRRONIUM BROMIDE; LAUDANOSINE; MIVACURIUM; MUSCARINIC RECEPTOR BLOCKING AGENT; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; PLACEBO; QUINOLINIC ACID DERIVATIVE; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VECURONIUM;

BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; LUNG DISEASE; MICROALBUMINURIA; MYOGLOBINURIA; NEUROMUSCULAR BLOCKING; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING;

ANESTHESIA RECOVERY PERIOD; GAMMA-CYCLODEXTRINS; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION;

EID: 61849122286     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2008.05871.x     Document Type: Review

References (65)

1. Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. British Journal of Anaesthesia 1992; 68: 492-8.
2. Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. British Journal of Anaesthesia 1994; 73: 613-8.
3. Ryan DW. Preoperative serum cholinesterase concentration in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing renal transplant. British Journal of Anaesthesia 1977; 49: 945-9.
4. Viby-Mogensen J, Hanel HK. Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesthesiologica Scandinavica 1978; 22: 371-80.
5. Yentis SM. Suxamethonium and hyperkalaemia. Anaesthesia and Intensive Care 1990; 18: 92-101.
6. Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesthesia and Analgesia 2000; 91: 237-41.
7. Blanc VF, Vaillancourt G, Brisson G. Succinylcholine, fasciculations and myoglobinaemia. Canadian Anaesthetic Society Journal 1986; 33: 178-84.
8. Gramstad L. Atracurium, vecuronium and pancuronium in end-stage renal failure. Dose-response properties and interactions with azathioprine. British Journal of Anaesthesia 1987; 59: 995-1003.
9. Duvaldestin P, Henzel D. Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and in patients with cirrhosis. British Journal of Anaesthesia 1982; 54: 513-6.
10. Khalil M, D'Honneur G, Duvaldestin P, Slavov V, De Hys C, Gomeni R. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994; 80: 1241-7.
11. Donati F. Onset of action of relaxants. Canadian Journal of Anaesthesia 1988; 35: S52-8.
12. Miller RD, Matteo RS, Benet LZ, Sohn YJ. The pharmacokinetics of d-tubocurarine in man with and without renal failure. Journal of Pharmacology and Experimental Therapeutics 1977; 202: 1-7.
13. Brotherton WP, Matteo RS. Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure. Anesthesiology 1981; 55: 273-6.
14. Diefenbach C, Kunzer T, Buzello W, Theisohn M. Alcuronium: a pharmacodynamic and pharmacokinetic update. Anesthesia and Analgesia 1995; 80: 373-7.
15. Cashman JN, Luke JJ, Jones RM. Neuromuscular block with doxacurium (BW A938U) in patients with normal or absent renal function. British Journal of Anaesthesia 1990; 64: 186-92.
16. Hunter JM, Jones RS, Utting JE. Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. British Journal of Anaesthesia 1984; 56: 941-51.
17. Miller RD, Cullen DJ. Renal failure and postoperative respiratory failure: recurarization? British Journal of Anaesthesia 1976; 48: 253-6.
18. Shearer ES, O'Sullivan EP, Hunter JM. Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration. British Journal of Anaesthesia 1991; 67: 569-73.
19. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984; 61: 699-702.
20. Parker CJ, Hunter JM. Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. British Journal of Anaesthesia 1989; 62: 177-83.
21. Bell CF, Hunter JM, Jones RS, Utting JE. Use of atracurium and vecuronium in patients with oesophageal varices. British Journal of Anaesthesia 1985; 57: 160-8.
22. Eastwood NB, Boyd AH, Parker CJ, Hunter JM. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. British Journal of Anaesthesia 1995; 75: 431-5.
23. Boyd AH, Eastwood NB, Parker CJ, Hunter JM. Pharmacodynamics of the 1R cis-1'R cis isomer of atracurium (51W89) in health and chronic renal failure. British Journal of Anaesthesia 1995; 74: 400-4.
24. De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. British Journal of Anaesthesia 1996; 76: 624-8.
25. Chapple DJ, Miller AA, Ward JB, Wheatley PL. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. British Journal of Anaesthesia 1987; 59: 218-25.
26. Ward S, Boheimer N, Weatherley BC, Simmonds RJ, Dopson TA. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. British Journal of Anaesthesia 1987; 59: 697-706.
27. Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM. Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. British Journal of Anaesthesia 1995; 75: 31-6.
28. Duvaldestin P, Agoston S, Henzel D, Kersten UW, Desmonts JM. Pancuronium pharmacokinetics in patients with liver cirrhosis. British Journal of Anaesthesia 1978; 50: 1131-6.
29. McLeod K, Watson MJ, Rawlins MD. Pharmacokinetics of pancuronium in patients with normal and impaired renal function. British Journal of Anaesthesia 1976; 48: 341-5.
30. Somogyi AA, Shanks CA, Triggs EJ. The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. European Journal of Clinical Pharmacology 1977; 12: 23-9.
31. Geha DG, Blitt CD, Moon BJ. Prolonged neuromuscular blockade with pancuronium in the presence of acute renal failure: a case report. Anesthesia and Analgesia 1976; 55: 343-5.
32. Sangala W, Dixon J. Pancuronium and renal failure. Anaesthesia 1987; 42: 1236.
33. Ward ME, Adu-Gyamfi Y, Strunin L. Althesin and pancuronium in chronic liver disease. British Journal of Anaesthesia 1975; 47: 1199-204.
34. Bencini AF, Scaf AH, Sohn YJ, et al. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesthesia and Analgesia 1986; 65: 245-51.
35. Lynam DP, Cronnelly R, Castagnoli KP, et al. The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 1988; 69: 227-31.
36. Smith CL, Hunter JM, Jones RS. Vecuronium infusions in patients with renal failure in an ITU. Anaesthesia 1987; 42: 387-93.
37. Arden JR, Lynam DP, Castagnoli KP, Canfell PC, Cannon JC, Miller RD. Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology 1988; 68: 771-6.
38. Hunter JM, Parker CJ, Bell CF, Jones RS, Utting JE. The use of different doses of vecuronium in patients with liver dysfunction. British Journal of Anaesthesia 1985; 57: 758-64.
39. Lebrault C, Berger JL, D'Hollander AA, Gomeni R, Henzel D, Duvaldestin P. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology 1985; 62: 601-5.
40. Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Canadian Journal of Anaesthesia 1991; 38: 430-5.
41. Mirakhur RK. Safety aspects of non-depolarizing neuromuscular blocking agents with special reference to rocuronium bromide. European Journal of Anaesthesiology Supplement 1994; 9: 133-40.
42. Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. European Journal of Anaesthesiology 2005; 22: 4-10.
43. Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. British Journal of Anaesthesia 1993; 71: 222-6.
44. Magorian T, Wood P, Caldwell J, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesthesia and Analgesia 1995; 80: 754-9.
45. Servin FS, Lavaut E, Kleef U, Desmonts JM. Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. Anesthesiology 1996; 84: 1092-100.
46. van Miert MM, Eastwood NB, Boyd AH, Parker CJ, Hunter JM. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. British Journal of Clinical Pharmacology 1997; 44: 139-44.
47. Suresh D, Carter JA, Whitehead JP, Goldhill DR, Flynn PJ. Cardiovascular changes at antagonism of atracurium. Effects of different doses of premixed neostigmine and glycopyrronium in a ratio of 5:1. Anaesthesia 1991; 46: 877-80.
48. Cronnelly R, Stanski DR, Miller RD, Sheiner LB, Sohn YJ. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 1979; 51: 222-6.
49. Morris RB, Cronnelly R, Miller RD, Stanski DR, Fahey MR. Pharmacokinetics of edrophonium in anephric and renal transplant patients. British Journal of Anaesthesia 1981; 53: 1311-4.
50. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia and Analgesia 2007; 104: 575-81.
51. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
52. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by Sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106: 935-43.
53. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with Sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. British Journal of Anaesthesia 2008; 100: 622-30.
54. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesthesia and Analgesia 2007; 104: 569-74.
55. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesthesia and Analgesia 2007; 104: 555-62.
56. Puhringer FA, Rex C, Sielenkamper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by Sugammadex at two different time points. Anesthesiology 2008; 109: 188-97.
57. Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesthesia and Analgesia 2007; 104: 582-4.
58. Bom A, van Egmond J, Hope F, Van de Pol F. Rapid reversal of rocuronium-induced neuromuscular blockade by Org 25969 is independent of renal function. Anesthesiology 2003; 99: A1158.
59. Staals L, Snoek M, Driessen J, Flockton E, Heeringa M, Hunter J. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. British Journal of Anaesthesia 2008; 101: 492-7.
60. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-74.
61. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. British Journal of Anaesthesia 2008; 100: 373-9.
62. Dahl V, Pendeville PE, Hollman MW, Heier T, Blobner M. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. Anesthesiology 2007; 107: A1581.
63. De Kam P, Van Kuijk J, Smeets J, Thomsen T, Peeters P. Single IV sugammadex doses up to 32 mg/kg are not associated with Qt/QTc prolongation. Anesthesiology 2007; 107: A1580.
64. De Kam P, Van Kuijk J, Prohn M, Thomsen T, Peeters P. Single IV sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium are not associated with QTc prolongation. European Journal of Anaesthesiology 2008; 25: 9AP5-9.
65. Amao R, Zornow MH, Cowan RM, Cheng DCH, Allard M. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology 2007; 107: A1582.